Skip to main content
Top
Published in: Advances in Therapy 7/2017

Open Access 01-07-2017 | Original Research

Resource Utilization Among Glaucoma Patients in the UK Treated with Beta-Blocker and Non-Beta-Blocker Adjunctive Therapy: A Retrospective Cohort Analysis

Authors: Ananth Viswanathan, Claudio Spera, Anmol Mullins, David Covert, Judit Banhazi, Paul McDwyer, Eibhlin Hudson, Alberto Ferreira

Published in: Advances in Therapy | Issue 7/2017

Login to get access

Abstract

Introduction

Few studies have examined outcomes and potential complications among glaucoma patients who are prescribed topical beta-blockers. This study examined resource usage (number of GP visits and hospitalizations) and diagnoses of respiratory or cardiovascular conditions among glaucoma patients prescribed beta-blockers compared to patients not prescribed beta-blockers.

Methods

A retrospective cohort analysis was conducted using data from the UK Clinical Practice Research Datalink (CPRD) database over the period January 1, 2006 to March 31, 2014. Adult patients with at least one diagnosis of glaucoma were categorized into beta-blocker users and non-beta-blocker users. Beta-blocker users were further separated into patients that maintained beta-blocker therapy and patients that discontinued beta-blocker treatment in year 2 of the post-index period. The CPRD data was queried directly to obtain the number of GP visits, and hospitalizations were extracted by linking the CPRD and Hospital Episode Statistics (HES) patient-level data.

Results

In the 12 months after being prescribed beta-blockers, patients that later discontinued beta-blocker treatment had a significantly higher average number of hospitalizations than patients that maintained beta-blocker therapy and the non-beta-blocker users (p < 0.05). In the year after beta-blocker initiation, there was a statistically significant within-group difference pre- and post-beta-blocker initiation for all groups, but the greatest number of GP visits occurred in the patients that subsequently discontinued beta-blocker treatment (mean 19.27). Patients that discontinued beta-blocker treatment were significantly more likely to have cardiovascular events than non-beta-blocker users in the post-index period (p < 0.05).

Conclusion

This study suggests that the introduction of beta-blockers in a certain group of patients who later discontinue their use is associated with increased use of medical resources (higher number of GP visits and hospitalizations) in glaucoma patients in the UK, which may be indicative of a potential relationship between use of topical beta-blockers in glaucoma therapy and adverse outcomes.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye. 2010;24(11):1692–9.CrossRefPubMed Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007–March 2008. Eye. 2010;24(11):1692–9.CrossRefPubMed
4.
go back to reference Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.CrossRefPubMed Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health. 2013;1:e339–49.CrossRefPubMed
5.
go back to reference Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–72.CrossRefPubMed Leske MC, Heijl A, Hyman L, Bengtsson B, Dong L, Yang Z. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:1965–72.CrossRefPubMed
6.
go back to reference Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRefPubMed Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRefPubMed
9.
go back to reference Owen CG, Carey IM, De Wilde S, Whincup PH, Wormald R, Cook DG. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol. 2006;90(7):861–8.CrossRefPubMedPubMedCentral Owen CG, Carey IM, De Wilde S, Whincup PH, Wormald R, Cook DG. The epidemiology of medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994 to 2003. Br J Ophthalmol. 2006;90(7):861–8.CrossRefPubMedPubMedCentral
10.
go back to reference Houde M, Castilloux AM, Tingey D, Assalian A, LeLorier J. Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. Can J Ophthalmol. 2003;38(6):469–75.CrossRefPubMed Houde M, Castilloux AM, Tingey D, Assalian A, LeLorier J. Prescription of topical antiglaucoma agents for patients with contraindications to beta-blockers. Can J Ophthalmol. 2003;38(6):469–75.CrossRefPubMed
11.
go back to reference Vinker S, Kaiserman I, Waitman DA, Blackman S, Kitai E. Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: does a central electronic medical record make a difference? Clin Drug Investig. 2006;26(9):495–500.CrossRefPubMed Vinker S, Kaiserman I, Waitman DA, Blackman S, Kitai E. Prescription of ocular beta-blockers in patients with obstructive pulmonary disease: does a central electronic medical record make a difference? Clin Drug Investig. 2006;26(9):495–500.CrossRefPubMed
12.
go back to reference Schmier JK, Covert DW, Lau EC. Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma. Clin Drug Investig. 2012;32(12):835–42.CrossRefPubMed Schmier JK, Covert DW, Lau EC. Medical service encounters and payments associated with topical adjunctive therapy use of timolol for glaucoma. Clin Drug Investig. 2012;32(12):835–42.CrossRefPubMed
13.
go back to reference Tate AR, Beloff N, Al-Radwan B, et al. Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. JAMIA. 2014;21(2):292–8.PubMed Tate AR, Beloff N, Al-Radwan B, et al. Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. JAMIA. 2014;21(2):292–8.PubMed
14.
go back to reference Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining co-morbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMed Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining co-morbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9.CrossRefPubMed
Metadata
Title
Resource Utilization Among Glaucoma Patients in the UK Treated with Beta-Blocker and Non-Beta-Blocker Adjunctive Therapy: A Retrospective Cohort Analysis
Authors
Ananth Viswanathan
Claudio Spera
Anmol Mullins
David Covert
Judit Banhazi
Paul McDwyer
Eibhlin Hudson
Alberto Ferreira
Publication date
01-07-2017
Publisher
Springer Healthcare
Published in
Advances in Therapy / Issue 7/2017
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-017-0541-8

Other articles of this Issue 7/2017

Advances in Therapy 7/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.